Eli Lilly has agreed to pay $62 million to 33 states to settle claims that it improperly marketed Zyprexa, its top-selling drug, to patients who did not have schizophrenia or bipolar disorder, its only approved uses.
Illinois will receive nearly $3.6 million in settlement funds from the company. Missouri will receive $1.5 million.
Lilly also agreed to several mandates that will last until 2014, well beyond the expiration of Zyprexa’s patent in 2011. The company agreed to avoid making false, misleading or deceptive claims about the drug and not to promote it outside FDA-approved uses.
This entry was posted
on Sunday, October 26th, 2008 at 8:19 am and is filed under Big Muddy River Newsletter.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.
